GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ADPT · Jun 30, 2026

Adaptive Biotechnologies Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]
Inspectable configuration

State dimensions

Filing0001193125-26-332940General Corporate
Debt relative to revenueRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.debt_to_revenue

0.00% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensity25thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

1.65% · OPTIONAL · VALID

Operating cash generation95thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-8.94% · OPTIONAL · VALID

Revenue growth55thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

21.53% · CORE · VALID

Inventory pressure35thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

14.67% · OPTIONAL · VALID

Gross margin80thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.gross_margin

71.82% · CORE · VALID

Operating margin90thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

-22.04% · CORE · VALID

R&D intensity5thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

26.77% · OPTIONAL · VALID

SBC intensity5thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

15.54% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History29 statesSelf-history eligible
Sep 30, 20217/8 normalizedLevel 3Dec 31, 20217/8 normalizedLevel 3Mar 31, 20227/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/9 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/9 normalizedLevel 3Mar 31, 20258/9 normalizedLevel 3Jun 30, 20258/9 normalizedLevel 3Sep 30, 20258/9 normalizedLevel 3Dec 31, 20258/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 4
Period transition

What moved in the state?

Balance Sheet Leverage Decreased
Previous
184.20%
Current
0.00%
Delta
-184.20%
Capex Intensity Increased
Previous
1.12%
Current
1.65%
Delta
0.53%
Cash Generation Increased
Previous
-13.46%
Current
-8.94%
Delta
4.51%
Growth Decreased
Previous
35.14%
Current
21.53%
Delta
-13.62%
Inventory Pressure Decreased
Previous
15.81%
Current
14.67%
Delta
-1.14%
Margin Decreased
Previous
73.60%
Current
71.82%
Delta
-1.79%
Profitability Increased
Previous
-27.10%
Current
-22.04%
Delta
5.06%
R And D Intensity Decreased
Previous
33.33%
Current
26.77%
Delta
-6.56%
Sbc Intensity Decreased
Previous
16.83%
Current
15.54%
Delta
-1.29%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Mar 31, 2026
Similarity
96%
Compared
8 dimensions
Coverage
100%
Growth 10.0 · Margin 5.0 · Profitability 0.0 · Sbc Intensity 0.0 · Capex Intensity 5.0 · Cash Generation 0.0 · R And D Intensity 0.0 · Inventory Pressure 0.0
Jun 30, 2025
Similarity
86%
Compared
8 dimensions
Coverage
100%
Growth 25.0 · Margin 10.0 · Profitability 10.0 · Sbc Intensity 0.0 · Capex Intensity 20.0 · Cash Generation 5.0 · R And D Intensity 5.0 · Inventory Pressure 15.0
Sep 30, 2024
Similarity
77%
Compared
8 dimensions
Coverage
100%
Growth 21.5 · Margin 45.0 · Profitability 5.0 · Sbc Intensity 30.0 · Capex Intensity 25.0 · Cash Generation 10.0 · R And D Intensity 5.0 · Inventory Pressure 10.0
Sep 30, 2022
Similarity
67%
Compared
8 dimensions
Coverage
100%
Growth 0.6 · Margin 56.9 · Profitability 13.1 · Sbc Intensity 71.9 · Capex Intensity 8.3 · Cash Generation 3.3 · R And D Intensity 5.0 · Inventory Pressure 3.5
Mar 31, 2024
Similarity
62%
Compared
8 dimensions
Coverage
100%
Growth 15.0 · Margin 64.2 · Profitability 26.8 · Sbc Intensity 73.9 · Capex Intensity 25.0 · Cash Generation 11.7 · R And D Intensity 5.5 · Inventory Pressure 8.7
Research Graph

Related governed research

Analogous To · ADPT state analogue 4 →Analogous To · ADPT state analogue 3 →Compared To · Biological Products, (No Diagnostic Substances) peers →Analogous To · ADPT state analogue 5 →Analogous To · ADPT state analogue 2 →Analogous To · ADPT state analogue 1 →Derived From · ADPT Company Quality Vector →Has State · Adaptive Biotechnologies Corp →Transitioned To · ADPT Fundamental State →Transitioned To · ADPT BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ADPT CAPEX_INTENSITY_INCREASED →Transitioned To · ADPT CASH_GENERATION_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.